Jack Williams, MD
Otolaryngology · Chevy Chase, MDNPI 1598738189
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,772 of the $3,746 with a category attached, or 74.0%. 17 manufacturers reported payments, led by Sanofi at 45.2% of the total. Reporting peaked in 2023 at $1,546 and has fallen 72.7% since, to $421 in 2025.
Across 127 payments — averaging $29.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$2K
- Optinose US, Inc.$624
- GSK$451
- Regeneron Healthcare Solutions, Inc.$324
- Kaleo, Inc.$126
- Medtronic$121
- plus $408 from 11 others
What the payments were for
- Consulting fees$97426%
- Food & beverage$2,77274%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 31 | $1,693 |
| Optinose US, Inc. | 39 | $624 |
| GSK | 19 | $451 |
| Regeneron Healthcare Solutions, Inc. | 13 | $324 |
| Kaleo, Inc. | 7 | $126 |
| Medtronic | 2 | $121 |
| Acclarent, Inc | 3 | $86 |
| Aerin Medical Inc. | 2 | $61 |
| Stryker | 1 | $54 |
| Smith+Nephew | 1 | $46 |
| Hikma Pharmaceuticals USA | 3 | $46 |
| Pfizer | 1 | $24 |
| Alk-abello, Inc | 1 | $24 |
| CSL Behring | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| AstraZeneca | 1 | $16 |
| Integra Lifesciences Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$974
How this compares
$3,746 in reported general payments places this provider in the 80th percentile of 222 otolaryngology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ipratropium Bromide | 46 | $2,426 |
| Pantoprazole Sodium | 82 | $2,264 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 20 | $2,206 |
| Azelastine Hcl | 11 | $486 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 34 | $422 |
| Cefdinir | 26 | $388 |
| Fluticasone Propionate | 12 | $237 |
| Prednisone | 21 | $98 |
| Montelukast Sodium | 11 | $61 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Chevy Chase
- Seth OringherChevy Chase$429K
- Natalie EarlChevy Chase$14K
- Philip SchoenfeldChevy Chase$5K
- Jessica ShenChevy Chase$4K
- Thomas WinklerChevy Chase$3K
- Marc DubinBaltimore$350K
- Douglas RehLutherville Timonium$231K
- Patrick HaBaltimore$41K
- Joshua LevyBethesda$40K
- Andrew LaneBaltimore$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.